These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9792136)

  • 61. [The effect of mepartricin on prostatic adenoma].
    Pellet B; Granata F; von Niederhäusern W
    Rev Med Suisse Romande; 1980 Nov; 100(11):899-903. PubMed ID: 6162182
    [No Abstract]   [Full Text] [Related]  

  • 62. [Double-blind study on the effects of mepartricin (SPA-S-160) versus placebo in the treatment of obstruction caused by adenoma of the prostate].
    Rizzo M; Tosto A; Dattolo E; Serni S
    Minerva Urol Nefrol; 1988; 40(2 Suppl):21-2. PubMed ID: 2460940
    [No Abstract]   [Full Text] [Related]  

  • 63. Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study.
    Vahlensieck W; Theurer C; Pfitzer E; Patz B; Banik N; Engelmann U
    Urol Int; 2015; 94(3):286-95. PubMed ID: 25196580
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
    Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
    Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Using a treatment satisfaction measure in an early trial to inform the evaluation of a new treatment for benign prostatic hyperplasia.
    Hareendran A; Abraham L
    Value Health; 2005; 8 Suppl 1():S35-40. PubMed ID: 16336487
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L.
    Deng L; Zong W; Tao X; Liu S; Feng Z; Lin Y; Liao Z; Chen M
    J Ethnopharmacol; 2019 Mar; 232():1-10. PubMed ID: 30529422
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
    Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP
    Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Serenoa repens for benign prostatic hyperplasia.
    Wilt T; Ishani A; Stark G; MacDonald R; Mulrow C; Lau J
    Cochrane Database Syst Rev; 2000; (2):CD001423. PubMed ID: 10796790
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [BPH pharmacotherapy (miscellaneous)].
    Okada H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():367-72. PubMed ID: 12599602
    [No Abstract]   [Full Text] [Related]  

  • 70. [Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study].
    Bauer HW; Casarosa C; Cosci M; Fratta M; Blessmann G
    MMW Fortschr Med; 1999 Jun; 141(25):62. PubMed ID: 10897913
    [No Abstract]   [Full Text] [Related]  

  • 71. A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia.
    Kadow C; Abrams PH
    Eur Urol; 1986; 12(3):187-9. PubMed ID: 2423337
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Saw palmetto for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 1999 Feb; 41(1046):18. PubMed ID: 10050179
    [No Abstract]   [Full Text] [Related]  

  • 73. [Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial].
    Lopatkin NA; Sivkov AV; Medvedev AA; Walter K; Schlefke S; Avdeĭchuk IuI; Golubev GV; Mel'nik KP; Elenberger NA; Engelman U
    Urologiia; 2006; (2):12, 14-9. PubMed ID: 16708583
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement.
    Shore N; Tutrone R; Efros M; Bidair M; Wachs B; Kalota S; Freedman S; Bailen J; Levin R; Richardson S; Kaminetsky J; Snyder J; Shepard B; Goldberg K; Hay A; Gange S; Grunberger I
    World J Urol; 2018 May; 36(5):801-809. PubMed ID: 29380128
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
    Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016 Dec; 15(12):1661-1670. PubMed ID: 27232207
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
    Marberger MJ
    Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials.
    Vlachopoulos C; Oelke M; Maggi M; Mulhall JP; Rosenberg MT; Brock GB; Esler A; Büttner H
    Int J Clin Pract; 2015 Dec; 69(12):1496-507. PubMed ID: 26299520
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Double-blind randomized placebo-controlled study of Bixa orellana in patients with lower urinary tract symptoms associated to benign prostatic hyperplasia.
    Zegarra L; Vaisberg A; Loza C; Aguirre RL; Campos M; Fernandez I; Talla O; Villegas L
    Int Braz J Urol; 2007; 33(4):493-500; discussion 501. PubMed ID: 17767753
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia.
    Dutkiewicz S
    Int Urol Nephrol; 1996; 28(1):49-53. PubMed ID: 8738619
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review.
    Ilic D; Misso M
    Maturitas; 2012 Aug; 72(4):269-76. PubMed ID: 22633187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.